Filing Details
- Accession Number:
- 0000899243-21-034817
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-01 19:51:18
- Reporting Period:
- 2021-08-30
- Accepted Time:
- 2021-09-01 19:51:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1568651 | Oscar Health Inc. | OSCR | Hospital & Medical Service Plans (6324) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1844181 | Joshua Kushner | 75 Varick Street, 5Th Floor New York NY 10013 | Co-Founder And Vice Chairman | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2021-08-30 | 274,697 | $14.68 | 1,997,676 | No | 4 | P | Indirect | See footnote |
Class A Common Stock | Acquisiton | 2021-08-30 | 55,188 | $15.27 | 2,052,864 | No | 4 | P | Indirect | See footnote |
Class A Common Stock | Acquisiton | 2021-08-31 | 93,836 | $14.81 | 2,146,700 | No | 4 | P | Indirect | See footnote |
Class A Common Stock | Acquisiton | 2021-08-31 | 211,703 | $15.43 | 2,358,403 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Footnotes
- Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII.
- Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.
- Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII.
- Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII.
- Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII.